Parkside Financial Bank & Trust Increases Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Parkside Financial Bank & Trust grew its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 806.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 979 shares of the company’s stock after buying an additional 871 shares during the period. Parkside Financial Bank & Trust’s holdings in Amphastar Pharmaceuticals were worth $36,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Aurora Investment Counsel grew its stake in Amphastar Pharmaceuticals by 0.4% during the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock valued at $2,654,000 after acquiring an additional 232 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after purchasing an additional 301 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. grew its position in shares of Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after purchasing an additional 398 shares in the last quarter. KBC Group NV increased its holdings in shares of Amphastar Pharmaceuticals by 43.1% in the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after purchasing an additional 650 shares during the last quarter. Finally, Sanctuary Advisors LLC lifted its position in shares of Amphastar Pharmaceuticals by 8.5% in the third quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock worth $466,000 after buying an additional 801 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Down 3.2 %

Shares of NASDAQ AMPH opened at $27.52 on Tuesday. Amphastar Pharmaceuticals, Inc. has a 1-year low of $26.98 and a 1-year high of $53.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The business’s 50 day moving average is $34.74 and its two-hundred day moving average is $42.57. The stock has a market capitalization of $1.32 billion, a P/E ratio of 9.17, a PEG ratio of 2.19 and a beta of 0.81.

Insider Transactions at Amphastar Pharmaceuticals

In other news, EVP Rong Zhou sold 7,000 shares of the stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total value of $310,940.00. Following the sale, the executive vice president now owns 118,469 shares of the company’s stock, valued at approximately $5,262,392.98. This represents a 5.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total transaction of $437,700.00. Following the completion of the sale, the director now owns 30,471 shares of the company’s stock, valued at $1,333,715.67. This trade represents a 24.71 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 27.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AMPH. Piper Sandler cut Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the company from $66.00 to $36.00 in a report on Tuesday, February 4th. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 target price for the company. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $50.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.